AG真人官方

On 29 July 2025, U-BX Technology Ltd. (symbol: UBXG) filed a Form 6-K announcing that its Board of Directors approved and adopted a new 2025 Equity Incentive Plan, effective the same day. No financial results or share-based figures were disclosed in the filing; the complete plan is provided as Exhibit 99.1.

The sole purpose of this report is to notify investors of the plan鈥檚 adoption, which is expected to grant equity awards to employees, directors and other service providers. Potential effects include improved talent retention and possible future share dilution, but specific terms鈥攕uch as award limits, eligibility criteria or dilution caps鈥攚ere not included in the 6-K text.

Data Storage Corp. (DTST/DTSTW) filed a Schedule TO-C disclosing plans for an issuer tender offer that will begin only after shareholders approve the proposed divestiture of the company鈥檚 cloud solutions business at the 10 Sep 2025 annual meeting. If the sale closes, the company intends to deploy 85 % of its cash on hand鈥攊ncluding the net divestiture proceeds鈥攖o repurchase up to 85 % of every shareholder鈥檚 common shares, potentially removing a large portion of the float.

The filing is strictly a pre-commencement communication; no price, timing or proration terms are yet available. Formal tender documents (Offer to Purchase, Letter of Transmittal, etc.) will be filed later on Schedule TO and provided free via the SEC and the company website. Until then, this notice is neither an offer to buy nor a solicitation to sell shares.

On 07/22/2025 Medicus Pharma Ltd. (MDCX) filed a Form 4 for Chief Financial Officer James P. Quinlan. The Board granted Quinlan 50,000 new stock options at a US$3.08 exercise price, vesting quarterly over one year and expiring 07/22/2030. The Board simultaneously accelerated vesting of a prior grant of 20,000 options issued 12/17/2024 at US$2.75 (CAD $3.95) so that they are now fully vested. After these transactions the CFO beneficially owns 70,000 options, all held directly; no common shares were bought or sold. The filing reflects routine equity compensation designed to align management incentives with shareholder value. Should all options be exercised, up to 70,000 additional shares could be issued, representing modest dilution relative to the company鈥檚 total share count (not disclosed in this filing).

Medicus Pharma Ltd. (MDCX) filed a Form 4 on 24 Jul 2025 for director Sara R. May.

• New grant: 25,000 stock options acquired on 22 Jul 2025 at an exercise price of US$3.08; vest quarterly over one year; expire 22 Jul 2030.
• Accelerated vesting: Board accelerated a prior 15,000-option grant dated 17 Dec 2024, exercise price US$2.75 (converted from C$3.95); all options now fully vested, expire 17 Dec 2029.
• No open-market share transactions; activity limited to derivative awards.
• After the transactions Ms. May directly holds 40,000 fully vested options; no change reported in common share ownership.

The filing reflects routine director compensation with limited dilution (40k shares if exercised) and carries minimal fundamental impact for shareholders.

Medicus Pharma Ltd. (MDCX) filed a Form 4 on 24 Jul 2025 for director Sara R. May.

• New grant: 25,000 stock options acquired on 22 Jul 2025 at an exercise price of US$3.08; vest quarterly over one year; expire 22 Jul 2030.
• Accelerated vesting: Board accelerated a prior 15,000-option grant dated 17 Dec 2024, exercise price US$2.75 (converted from C$3.95); all options now fully vested, expire 17 Dec 2029.
• No open-market share transactions; activity limited to derivative awards.
• After the transactions Ms. May directly holds 40,000 fully vested options; no change reported in common share ownership.

The filing reflects routine director compensation with limited dilution (40k shares if exercised) and carries minimal fundamental impact for shareholders.

Safety Shot, Inc. (NASDAQ:SHOT) reported that on 21 Jul 2025 it signed a Securities Purchase Agreement for a registered direct offering of 22,993,492 common shares at $0.461 per share and a concurrent private placement of 45,986,984 unregistered five-year warrants priced at $0.125 each, exercisable at the same $0.461 strike. Together, the transactions closed on 24 Jul 2025 and generated gross proceeds of approximately $16.3 million before expenses.

Placement agent Dominari Securities LLC will receive an 8% cash commission, a 1% expense allowance and $150,000 for legal/out-of-pocket costs, plus 1,839,479 five-year warrants exercisable at $0.461. The company will file an S-1 within ten days to register the resale of warrant shares, with effectiveness required within 45 days (75 days if subject to full SEC review).

Use of proceeds: working capital and general corporate purposes. Assuming full warrant exercise, the deal could add up to 70.8 million new shares, materially diluting existing holders while improving near-term liquidity.

Kaiser Aluminum (KALU) Q2-25 10-Q key takeaways: Net sales rose 6 % YoY to $823.1 m while operating income improved to $38.0 m (+5 %). Net income climbed 23 % to $23.2 m; diluted EPS reached $1.41 versus $1.15. For the first six months, sales were $1.60 bn (+6 %), net income $44.8 m (+21 %) and EPS $2.72.

Gross profit held at 12.2 % of revenue; SG&A stayed roughly flat. Restructuring charges collapsed to $0.1 m from $6.8 m as the 2024 Sherman, TX exit wound down; the new 2025 cost-reduction plan has generated $1.9 m YTD (projected $2-3 m total).

Operating cash flow fell 19 % to $72.9 m, trailing cap-ex of $81.8 m and producing negative free cash flow. Cash on hand shrank to $13.1 m; $32.8 m was drawn on the $575 m revolver, lifting long-term debt to $1.08 bn and pushing net leverage near 6脳 annualised EBITDA.

The firm shifted from LIFO to weighted-average cost inventory accounting, applied retrospectively, boosting retained earnings and comparability. Derivative hedges added a $2.5 m COGS benefit and lifted AOCI to $27.2 m.

Stockholders鈥� equity expanded to $776 m despite $25.7 m of dividends ($0.77/sh each quarter). Environmental accruals total $18.2 m with a possible $13.4 m additional exposure. No guidance was provided.

Kaiser Aluminum (KALU) Q2-25 10-Q key takeaways: Net sales rose 6 % YoY to $823.1 m while operating income improved to $38.0 m (+5 %). Net income climbed 23 % to $23.2 m; diluted EPS reached $1.41 versus $1.15. For the first six months, sales were $1.60 bn (+6 %), net income $44.8 m (+21 %) and EPS $2.72.

Gross profit held at 12.2 % of revenue; SG&A stayed roughly flat. Restructuring charges collapsed to $0.1 m from $6.8 m as the 2024 Sherman, TX exit wound down; the new 2025 cost-reduction plan has generated $1.9 m YTD (projected $2-3 m total).

Operating cash flow fell 19 % to $72.9 m, trailing cap-ex of $81.8 m and producing negative free cash flow. Cash on hand shrank to $13.1 m; $32.8 m was drawn on the $575 m revolver, lifting long-term debt to $1.08 bn and pushing net leverage near 6脳 annualised EBITDA.

The firm shifted from LIFO to weighted-average cost inventory accounting, applied retrospectively, boosting retained earnings and comparability. Derivative hedges added a $2.5 m COGS benefit and lifted AOCI to $27.2 m.

Stockholders鈥� equity expanded to $776 m despite $25.7 m of dividends ($0.77/sh each quarter). Environmental accruals total $18.2 m with a possible $13.4 m additional exposure. No guidance was provided.

Kaiser Aluminum (KALU) Q2-25 10-Q key takeaways: Net sales rose 6 % YoY to $823.1 m while operating income improved to $38.0 m (+5 %). Net income climbed 23 % to $23.2 m; diluted EPS reached $1.41 versus $1.15. For the first six months, sales were $1.60 bn (+6 %), net income $44.8 m (+21 %) and EPS $2.72.

Gross profit held at 12.2 % of revenue; SG&A stayed roughly flat. Restructuring charges collapsed to $0.1 m from $6.8 m as the 2024 Sherman, TX exit wound down; the new 2025 cost-reduction plan has generated $1.9 m YTD (projected $2-3 m total).

Operating cash flow fell 19 % to $72.9 m, trailing cap-ex of $81.8 m and producing negative free cash flow. Cash on hand shrank to $13.1 m; $32.8 m was drawn on the $575 m revolver, lifting long-term debt to $1.08 bn and pushing net leverage near 6脳 annualised EBITDA.

The firm shifted from LIFO to weighted-average cost inventory accounting, applied retrospectively, boosting retained earnings and comparability. Derivative hedges added a $2.5 m COGS benefit and lifted AOCI to $27.2 m.

Stockholders鈥� equity expanded to $776 m despite $25.7 m of dividends ($0.77/sh each quarter). Environmental accruals total $18.2 m with a possible $13.4 m additional exposure. No guidance was provided.